WO2004039383A1 - 線維筋痛症治療剤 - Google Patents
線維筋痛症治療剤 Download PDFInfo
- Publication number
- WO2004039383A1 WO2004039383A1 PCT/JP2003/013999 JP0313999W WO2004039383A1 WO 2004039383 A1 WO2004039383 A1 WO 2004039383A1 JP 0313999 W JP0313999 W JP 0313999W WO 2004039383 A1 WO2004039383 A1 WO 2004039383A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fibromyalgia
- tissue
- extract
- vaccinia virus
- inoculated
- Prior art date
Links
- 208000001640 Fibromyalgia Diseases 0.000 title claims abstract description 37
- 239000000284 extract Substances 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 29
- 241000700618 Vaccinia virus Species 0.000 claims abstract description 27
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 12
- 206010061218 Inflammation Diseases 0.000 claims abstract description 10
- 230000004054 inflammatory process Effects 0.000 claims abstract description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 241000255789 Bombyx mori Species 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 5
- 239000005723 virus inoculator Substances 0.000 abstract 4
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 30
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000011282 treatment Methods 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010046865 Vaccinia virus infection Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000007089 vaccinia Diseases 0.000 description 5
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000003544 deproteinization Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
- 206010058009 Subacute myelo-opticoneuropathy Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- KSSNXJHPEFVKHY-UHFFFAOYSA-N phenol;hydrate Chemical compound O.OC1=CC=CC=C1 KSSNXJHPEFVKHY-UHFFFAOYSA-N 0.000 description 2
- RDYOACUIENLGER-UHFFFAOYSA-N phenol;propane-1,2,3-triol Chemical compound OCC(O)CO.OC1=CC=CC=C1 RDYOACUIENLGER-UHFFFAOYSA-N 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010068975 Bone atrophy Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000010321 sleep therapy Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
Definitions
- the present invention relates to a novel pharmaceutical use of an extract of inflamed tissue inoculated with vaccinia virus, and specifically, a therapeutic agent for fibromyalgia containing an extract of inflamed tissue inoculated with vaccinia virus as an active ingredient, fibromyalgia Use of an extract of inflamed tissue inoculated with vaccinia virus as an active ingredient for the manufacture of a pharmaceutical composition for treating sarcoidosis, and administration of a medicinal composition containing an extract of inflamed tissue inoculated with vaccinia virus as an active ingredient
- the present invention relates to a method for treating fibromyalgia. Background art
- Fibromyalgia is a disease with chronic and generalized pain, or partial or widespread chronic pain, which may cause pain not only in muscle tissue but also in the skin . Fibromyalgia often involves not only generalized chronic pain, but also fatigue, fatigue, depression, anxiety, morning stiffness, muscle stiffness, and sleep disorders. Also accompanied by symptoms such as headache, facial pain, cognitive impairment (memory difference, lack of concentration), gastrointestinal complaints (visceral pain, digestive disorders, flatulence), frequent urine, diarrhea, constipation, dysmenorrhea Sometimes.
- Fibromyalgia has a variety of subjective symptoms, but there are not many other objective findings other than the characteristic whole-body tenderness. In addition to imaging tests such as MR I and CT, pathological examination of myalgia sites, Immunological, virological and endocrinological examinations show almost no abnormalities.
- Fibromyalgia is a disease that is very different from many common painful diseases caused by noxious stimuli that may cause damage or damage to living tissue, and there are no pathological findings associated with the pain site. I can't.
- fibromyalgia For the treatment of fibromyalgia, most anti-inflammatory analgesics such as non-steroidal anti-inflammatory drugs (N S A I D s) commonly used for general pain treatment are not very effective.
- various drugs such as muscle relaxants, opioid analgesics, and anxiolytics have been tried, but their effectiveness varies greatly from person to person, and no significant effect has been observed. Therefore, the treatment of fibromyalgia currently includes antidepressants or prescription of NSAIDs, administration of local anesthetics or steroids to the site of pain, massage, exercise therapy, sleep therapy, etc. It ’s just that.
- the cause of fibromyalgia has not been identified, and there are large individual differences in therapeutic effects, and it has not been established as a therapeutic method.
- an object of the present invention is to provide a therapeutic agent that is highly safe and effective in the treatment of fibromyalgia without an effective therapeutic agent. Disclosure of the invention
- the present inventor has formulated a preparation containing an extract of inflammatory tissue inoculated with ⁇ cinnamon virus as an active ingredient in patients who have been diagnosed with fibromyalgia and have not been effective with existing drugs such as anti-inflammatory analgesics and antidepressants. As a result of administration, the preparation has a remarkable therapeutic effect on fibromyalgia. I found it.
- the present invention relates to a therapeutic agent for fibromyalgia comprising an extract of inflamed tissue inoculated with Waxure virus as an active ingredient.
- the present invention also relates to the use of an extract of inflamed tissue inoculated with vaccinia virus as an active ingredient for the manufacture of a pharmaceutical composition for treating fibromyalgia.
- the present invention relates to a method for treating fibromyalgia comprising administering to a patient a pharmaceutical composition containing an extract of inflamed tissue inoculated with vaccinia virus as an active ingredient.
- analgesic action sedative action, anti-stress action, anti-allergic action (see JP-A-53-101515), immune promoting action, anti-cancer action, cirrhosis Inhibitory action (see Japanese Laid-Open Patent Publication No. 55-87724, especially pages 3, 5 and 6), therapeutic effect for idiopathic thrombocytopenic purpura (see Japanese Patent Publication No. 1-265028, especially pages 1 and 2) ), Post-herpetic neuralgia, cerebral edema, dementia, spinocerebellar degeneration, etc.
- Inflammatory tissue extract inoculated with vaccinia virus is used to destroy tissue that has been inoculated with vaccinia virus, and after removing tissue fragments by adding extraction solvent, deproteinization treatment is performed and adsorbed It is obtained by adsorbing to the agent and then eluting the adsorbed components.
- the extract of inflamed tissue inoculated with Waxure virus is produced, for example, by the following process:
- the active ingredient of the therapeutic agent for fibromyalgia of the present invention is a non-proteinaceous biological function regulator extracted from vaccinia virus-infused tissue as described above, and is also described in the above-mentioned medical drug Japan Pharmaceutical Collection Vaccinia virus-inoculated rabbit inflammation skin extract preparations are commercially available with the approval of pharmaceutical manufacture.
- various vaccinia virus-inoculated inflammatory tissue extracts described in the above-mentioned patent publications and the like can be used in the present invention, and their production methods and preferred dosages are also described in the literature.
- the administration method to patients is preferably oral administration using tablets, but when the symptoms are particularly severe, intravenous injections or injectable injections are also used. Since the symptoms of fibromyalgia vary, the dosage form is not limited to oral.
- the dose should be set as appropriate according to the type of inflammatory tissue inoculated with vaccinia virus, but the dose approved for commercial preparations is the above-mentioned Japan Pharmaceutical Collection (pages 2 3 7 9). According to the standard, it has been shown that ethical drugs are given to administer 16 neurotropin units (NU) per day for internal use and 3.6 -6 to 7.2 NU per day for injections. The dose may be adjusted according to the type of disease, severity, individual differences among patients, administration method, administration period, etc.
- NU neurotropin units
- Example 1 The following is an example of a method for producing an inflamed tissue extract inoculated with vaccinia virus, and the results of a clinical test on a novel pharmacological action, that is, fibromyalgia.
- a novel pharmacological action that is, fibromyalgia.
- Example 2 Water was added to the activated carbon, and the pH was adjusted to 9.4 to 10 with sodium hydroxide. The mixture was stirred for 3 to 5 hours and then filtered. The filtrate was adjusted to pH 7.0-7.2 with hydrochloric acid and dried under reduced pressure to obtain an inflamed tissue extract inoculated with vaccinia virus.
- Example 2
- the skin of healthy mature rabbits was inoculated with vaccinia virus, and the bruised skin was exfoliated, crushed and added with phenol water. Next, this was filtered under pressure, and the obtained filtrate was adjusted to pH 5 with hydrochloric acid and then heat-treated at 90 to 100 ° C. for 30 minutes. After deproteinization by filtration, the solution was adjusted to pH 9 with sodium hydroxide, further heat-treated at 90 to 100 ° C. for 15 minutes, and then filtered. The filtrate was adjusted to about pH 4.5 with hydrochloric acid, added with 2% activated charcoal, stirred for 2 hours, and then centrifuged.
- Example 3 Water was added to the collected activated carbon, adjusted to pH 10 with sodium hydroxide, stirred at 60 ° C for 1.5 hours, and then centrifuged. Water was added to the collected activated carbon, and the pH was adjusted to pH 11 with sodium hydroxide. The mixture was stirred at 60 ° C for 1.5 hours and then centrifuged. The supernatant was neutralized with hydrochloric acid and then dried under reduced pressure to obtain an extract of inflamed tissue inoculated with rabbit vaccinia virus.
- Example 3 Water was added to the collected activated carbon, adjusted to pH 10 with sodium hydroxide, stirred at 60 ° C for 1.5 hours, and then centrifuged. Water was added to the collected activated carbon, and the pH was adjusted to pH 11 with sodium hydroxide. The mixture was stirred at 60 ° C for 1.5 hours and then centrifuged. The supernatant was neutralized with hydrochloric acid and then dried under reduced pressure to obtain an extract of inflamed tissue inoculated with rabbit vaccinia virus.
- the activated skin is aseptically peeled off, chopped and added with water, and then polished with a homogenizer to obtain a milky product. . Then filtered under pressure this, and the obtained filtrate was adjusted to pH 5. 0 with hydrochloric acid and heated at flow steam under 100 D C. After deproteinization by filtration, the solution was adjusted to pH 9.1 with sodium hydroxide, further heated at 100 ° C., and filtered. The filtrate was adjusted to pH 4.1 with hydrochloric acid, 2% activated carbon was added and stirred for 2 hours, followed by filtration. The filtrate was further added with 5.5% activated carbon and stirred for 2 hours, followed by filtration.
- Example 4 Inflammatory tissue extract inoculated with vaccinia virus was obtained by drying under reduced pressure
- L cells (mouse sarcoma cells) were transplanted subcutaneously into C 3 H mice, and 10 days later, vaccinia virus was inoculated at the same site, and 5 days later, the tumor inflammation site was excised. After mincing 100 g of the excised tissue, a 70% glycerin solution buffered with pH 7.0 was added, and it was abraded with a Warinda blender and freeze-thawed three times. The milky ground solution was centrifuged at 200 ° C. for 1 hour to remove the precipitate, the supernatant pH was adjusted to 5.0, heated to 100 ° C. and filtered. The filtrate was adjusted to pH 9.0, heated again to 100 ° C. and filtered to remove insoluble matters.
- the inflammatory skin extract liquid preparation [product name “Neurotropin Tablet” (registered trademark)] inoculated with vaccinia virus was administered.
- the dose was 4.0 tablets containing neurotropin units, 4 tablets a day, divided into two mornings and evenings, and were orally administered for 2-4 weeks.
- the effect was judged by listening to patient evaluation (VAS [Visual Analogue Scale] evaluation) to determine how much pain was reduced after administration, assuming pain before administration as “10”.
- VAS Visual Analogue Scale
- the vaccinia virus-inoculated inflammation tissue extract of the present invention showed a remarkable therapeutic effect on fibromyalgia. It should be noted that the disease improvement effect was observed in patients who did not receive any effect from any of the drug treatments attempted before the start of the above clinical trials.
- NSAIDs normal non-steroidal anti-inflammatory drugs
- side effects There is a demand for drugs that are rarely used and can be used with peace of mind.
- the drug of the present invention has been It is a novel therapeutic agent for fibromyalgia without a therapeutic drug, and is extremely useful as a highly safe drug with few side effects.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2503810A CA2503810C (en) | 2002-10-31 | 2003-10-31 | Therapeutic agent for fibromyalgia |
EP03770087.9A EP1566178B1 (en) | 2002-10-31 | 2003-10-31 | Remedy for fibromyalgia |
US10/532,792 US7148012B2 (en) | 2002-10-31 | 2003-10-31 | Therapeutic agent for fibromyalgia |
JP2004548103A JP3887731B2 (ja) | 2002-10-31 | 2003-10-31 | 線維筋痛症治療剤 |
AU2003280684A AU2003280684B2 (en) | 2002-10-31 | 2003-10-31 | Remedy for fibromyalgia |
US11/494,637 US7238487B2 (en) | 2002-10-31 | 2006-07-28 | Therapeutic agent for fibromyalgia |
US11/802,742 US7435547B2 (en) | 2002-10-31 | 2007-05-24 | Therapeutic agent for fibromyalgia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-317011 | 2002-10-31 | ||
JP2002317011 | 2002-10-31 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10532792 A-371-Of-International | 2003-10-31 | ||
US10/532,792 A-371-Of-International US7148012B2 (en) | 2002-10-31 | 2003-10-31 | Therapeutic agent for fibromyalgia |
US11/494,637 Division US7238487B2 (en) | 2002-10-31 | 2006-07-28 | Therapeutic agent for fibromyalgia |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004039383A1 true WO2004039383A1 (ja) | 2004-05-13 |
Family
ID=32211708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/013999 WO2004039383A1 (ja) | 2002-10-31 | 2003-10-31 | 線維筋痛症治療剤 |
Country Status (9)
Country | Link |
---|---|
US (3) | US7148012B2 (ja) |
EP (1) | EP1566178B1 (ja) |
JP (1) | JP3887731B2 (ja) |
KR (1) | KR101097138B1 (ja) |
CN (1) | CN100464782C (ja) |
AU (1) | AU2003280684B2 (ja) |
CA (1) | CA2503810C (ja) |
TW (1) | TWI342778B (ja) |
WO (1) | WO2004039383A1 (ja) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006095674A1 (ja) * | 2005-03-07 | 2006-09-14 | St. Marianna University School Of Medicine | 研究、判定又は評価方法 |
WO2007114230A1 (ja) | 2006-03-30 | 2007-10-11 | Kyoto University | チオレドキシン産生促進剤 |
WO2008029838A1 (en) | 2006-09-06 | 2008-03-13 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for study, determination or evaluation by gene expression analysis |
WO2008029836A1 (fr) * | 2006-09-06 | 2008-03-13 | Nippon Zoki Pharmaceutical Co., Ltd. | Procédé d'étude, de détermination ou d'évaluation |
WO2008041751A1 (fr) | 2006-10-05 | 2008-04-10 | St. Marianna University School Of Medicine | Préparation pharmaceutique pour le traitement de la fibromyalgie |
WO2009025091A1 (ja) * | 2007-08-23 | 2009-02-26 | St. Marianna University School Of Medicine | 線維筋痛症治療用医薬組成物 |
WO2009028605A1 (ja) | 2007-08-31 | 2009-03-05 | Kyushu University, National University Corporation | 抗がん剤による末梢神経障害の予防又は軽減剤 |
WO2011111770A1 (ja) | 2010-03-11 | 2011-09-15 | 日本臓器製薬株式会社 | 慢性前立腺炎、間質性膀胱炎及び/又は排尿障害の改善又は治療剤 |
WO2011162317A1 (ja) | 2010-06-25 | 2011-12-29 | 日本臓器製薬株式会社 | 被検物質の判定又は評価方法 |
US8293280B2 (en) | 2004-12-17 | 2012-10-23 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for treatment of HIV infection |
US8568789B2 (en) | 2004-12-01 | 2013-10-29 | Nippon Zoki Pharmaceutical Co., Ltd. | Dried product and a process for manufacturing the product |
WO2014057995A1 (ja) * | 2012-10-10 | 2014-04-17 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
JP2014077779A (ja) * | 2013-04-19 | 2014-05-01 | Nippon Zoki Pharmaceut Co Ltd | 抽出物及び製剤 |
WO2014178394A1 (ja) * | 2013-04-30 | 2014-11-06 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
JP2014214154A (ja) * | 2013-08-23 | 2014-11-17 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
JP2014214155A (ja) * | 2013-11-19 | 2014-11-17 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
JP2016033145A (ja) * | 2015-11-20 | 2016-03-10 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
JP2016216518A (ja) * | 2016-09-28 | 2016-12-22 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
JPWO2017131169A1 (ja) * | 2016-01-29 | 2019-01-17 | 国立大学法人千葉大学 | 筋損傷の予防又は治療剤 |
US10711292B2 (en) | 2010-10-14 | 2020-07-14 | Nikkon Zoki Pharmaceutical Co., Ltd. | Method for promoting the synthesis of collagen and proteoglycan in chondrocytes |
US11207354B2 (en) | 2016-09-23 | 2021-12-28 | Osaka University | Schwann cell differentiation promoting agent and a peripheral nerve regeneration promoting agent |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009085968A1 (en) * | 2007-12-19 | 2009-07-09 | Great Lakes Biosciences, Llc | Brain-related chronic pain disorder diagnosis and assessment method |
CN102027625B (zh) * | 2008-04-07 | 2017-05-03 | 卡内基美浓大学 | 钠离子为主的水相电解质电化学二次能源储存装置 |
EP2286810A4 (en) * | 2008-05-16 | 2011-07-20 | Axis Inc | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FIBROMYALGIA |
TWI711456B (zh) * | 2015-05-29 | 2020-12-01 | 日商日本臟器製藥股份有限公司 | 牛痘病毒接種炎症組織萃取物及其用途以及其判定或評估方法 |
EP3421989A4 (en) * | 2016-02-24 | 2019-08-14 | Osaka University | TEST METHODS |
US10376050B2 (en) * | 2017-12-22 | 2019-08-13 | Purpose Built, Inc. | Multi-functional kitchen device |
JP2022521125A (ja) * | 2019-01-30 | 2022-04-06 | ジュン リウ | 脳内の炎症の抑制又は軽減剤 |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53101515A (en) * | 1977-02-17 | 1978-09-05 | Nippon Zoki Pharmaceutical Co | Medicine having anodyne * sedative and antiallergic activity and production thereof |
JPS5587724A (en) * | 1978-12-27 | 1980-07-02 | Nippon Zoki Pharmaceut Co Ltd | Selective immune enhancer |
JPH01265028A (ja) * | 1988-04-15 | 1989-10-23 | Nippon Zoki Pharmaceut Co Ltd | 特発性血小板減少性紫斑病治療剤 |
EP0348353A2 (en) * | 1988-06-20 | 1989-12-27 | Nippon Zoki Pharmaceutical Co. Ltd. | The use of physiologically active substances for the manufacture of drugs for cerebral and neuronal diseases |
JPH0228119A (ja) * | 1988-07-15 | 1990-01-30 | Nippon Zoki Pharmaceut Co Ltd | 糖尿病性神経障害治療剤 |
EP0645152A2 (en) * | 1993-09-29 | 1995-03-29 | Sterling Winthrop Inc. | Disposable holder for pre-filled cartridge-needle unit |
JPH08291077A (ja) * | 1995-04-25 | 1996-11-05 | Nippon Zoki Pharmaceut Co Ltd | 骨萎縮改善剤 |
EP0852950A1 (en) * | 1997-01-08 | 1998-07-15 | Nippon Zoki Pharmaceutical Co., Ltd. | Nitrogen monoxide production suppressor |
EP0916344A2 (en) * | 1997-11-07 | 1999-05-19 | Nippon Zoki Pharmaceutical Co., Ltd. | Nef action inhibitor |
EP0953352A1 (en) * | 1998-04-27 | 1999-11-03 | Nippon Zoki Pharmaceutical Co., Ltd. | A therapeutic agent for ischemic diseases |
EP1038529A2 (en) * | 1999-03-19 | 2000-09-27 | Nippon Zoki Pharmaceutical Co., Ltd. | Agent for increasing chemokine production |
US6165515A (en) * | 1997-09-12 | 2000-12-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for treatment of osteoporosis |
JP2001058950A (ja) * | 1999-08-20 | 2001-03-06 | Fujimoto Brothers:Kk | サイトカイン調節剤 |
WO2001068643A2 (fr) * | 2000-03-16 | 2001-09-20 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Nouveaux derives heterocycliques ou benzeniques de l'acide lipoique, leur preparation et leur application a titre de medicaments |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US616515A (en) * | 1898-12-27 | williams | ||
JPS6339572A (ja) | 1986-08-05 | 1988-02-20 | 株式会社チノー | 葉たばこ乾燥装置 |
JP2651674B2 (ja) * | 1987-07-23 | 1997-09-10 | 日本臓器製薬 株式会社 | 新規生理活性物質及びその製造方法 |
JP2594222B2 (ja) | 1993-09-28 | 1997-03-26 | 日本臓器製薬株式会社 | 新規生理活性物質−kf |
JP2000016942A (ja) | 1998-04-27 | 2000-01-18 | Nippon Zoki Pharmaceut Co Ltd | 虚血性疾患治療剤 |
CN1055249C (zh) * | 1998-07-15 | 2000-08-09 | 沈继平 | 一种镇痛药和其制造方法 |
JP2000336034A (ja) | 1999-03-19 | 2000-12-05 | Nippon Zoki Pharmaceut Co Ltd | ケモカイン産生促進剤 |
US6521772B1 (en) * | 2001-09-27 | 2003-02-18 | Praxair Technology, Inc. | Synthesis of substituted ruthenocene complexes |
US6420583B1 (en) * | 2001-09-27 | 2002-07-16 | Praxair Technology, Inc | Methods of synthesizing ruthenium and osmium compounds |
US6809212B2 (en) * | 2002-06-12 | 2004-10-26 | Praxair Technology, Inc. | Method for producing organometallic compounds |
CN1207005C (zh) * | 2002-10-31 | 2005-06-22 | 威世药业(如皋)有限公司 | 含生物活性物质的兔皮和其用途 |
-
2003
- 2003-10-31 US US10/532,792 patent/US7148012B2/en not_active Expired - Lifetime
- 2003-10-31 KR KR1020057007363A patent/KR101097138B1/ko active IP Right Grant
- 2003-10-31 CN CNB200380102599XA patent/CN100464782C/zh not_active Expired - Lifetime
- 2003-10-31 WO PCT/JP2003/013999 patent/WO2004039383A1/ja active Application Filing
- 2003-10-31 TW TW092130544A patent/TWI342778B/zh not_active IP Right Cessation
- 2003-10-31 EP EP03770087.9A patent/EP1566178B1/en not_active Expired - Lifetime
- 2003-10-31 JP JP2004548103A patent/JP3887731B2/ja not_active Expired - Lifetime
- 2003-10-31 CA CA2503810A patent/CA2503810C/en not_active Expired - Fee Related
- 2003-10-31 AU AU2003280684A patent/AU2003280684B2/en not_active Ceased
-
2006
- 2006-07-28 US US11/494,637 patent/US7238487B2/en not_active Expired - Lifetime
-
2007
- 2007-05-24 US US11/802,742 patent/US7435547B2/en not_active Expired - Lifetime
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53101515A (en) * | 1977-02-17 | 1978-09-05 | Nippon Zoki Pharmaceutical Co | Medicine having anodyne * sedative and antiallergic activity and production thereof |
JPS5587724A (en) * | 1978-12-27 | 1980-07-02 | Nippon Zoki Pharmaceut Co Ltd | Selective immune enhancer |
JPH01265028A (ja) * | 1988-04-15 | 1989-10-23 | Nippon Zoki Pharmaceut Co Ltd | 特発性血小板減少性紫斑病治療剤 |
EP0348353A2 (en) * | 1988-06-20 | 1989-12-27 | Nippon Zoki Pharmaceutical Co. Ltd. | The use of physiologically active substances for the manufacture of drugs for cerebral and neuronal diseases |
JPH0228119A (ja) * | 1988-07-15 | 1990-01-30 | Nippon Zoki Pharmaceut Co Ltd | 糖尿病性神経障害治療剤 |
EP0645152A2 (en) * | 1993-09-29 | 1995-03-29 | Sterling Winthrop Inc. | Disposable holder for pre-filled cartridge-needle unit |
JPH08291077A (ja) * | 1995-04-25 | 1996-11-05 | Nippon Zoki Pharmaceut Co Ltd | 骨萎縮改善剤 |
EP0852950A1 (en) * | 1997-01-08 | 1998-07-15 | Nippon Zoki Pharmaceutical Co., Ltd. | Nitrogen monoxide production suppressor |
US6165515A (en) * | 1997-09-12 | 2000-12-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for treatment of osteoporosis |
EP0916344A2 (en) * | 1997-11-07 | 1999-05-19 | Nippon Zoki Pharmaceutical Co., Ltd. | Nef action inhibitor |
EP0953352A1 (en) * | 1998-04-27 | 1999-11-03 | Nippon Zoki Pharmaceutical Co., Ltd. | A therapeutic agent for ischemic diseases |
EP1038529A2 (en) * | 1999-03-19 | 2000-09-27 | Nippon Zoki Pharmaceutical Co., Ltd. | Agent for increasing chemokine production |
JP2001058950A (ja) * | 1999-08-20 | 2001-03-06 | Fujimoto Brothers:Kk | サイトカイン調節剤 |
WO2001068643A2 (fr) * | 2000-03-16 | 2001-09-20 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Nouveaux derives heterocycliques ou benzeniques de l'acide lipoique, leur preparation et leur application a titre de medicaments |
Non-Patent Citations (1)
Title |
---|
NISHIOKA MAKIKO ET AL.: "FMS/CSF to neurotropin no yukosei ni tsuite", RHEUMATISM, vol. 4, no. 2, April 2003 (2003-04-01), pages 331, XP002979106 * |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8568789B2 (en) | 2004-12-01 | 2013-10-29 | Nippon Zoki Pharmaceutical Co., Ltd. | Dried product and a process for manufacturing the product |
US8293280B2 (en) | 2004-12-17 | 2012-10-23 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for treatment of HIV infection |
JP2013050452A (ja) * | 2005-03-07 | 2013-03-14 | Nippon Zoki Pharmaceut Co Ltd | 研究、判定又は評価方法 |
WO2006095674A1 (ja) * | 2005-03-07 | 2006-09-14 | St. Marianna University School Of Medicine | 研究、判定又は評価方法 |
JP5607869B2 (ja) * | 2005-03-07 | 2014-10-15 | 日本臓器製薬株式会社 | 研究、判定又は評価方法 |
AU2006221453B2 (en) * | 2005-03-07 | 2011-08-25 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for study, determination or evaluation |
WO2007114230A1 (ja) | 2006-03-30 | 2007-10-11 | Kyoto University | チオレドキシン産生促進剤 |
KR101400063B1 (ko) | 2006-03-30 | 2014-05-26 | 니폰 조키 세야쿠 가부시키가이샤 | 티오레독신 산생 촉진제 |
US8338108B2 (en) | 2006-03-30 | 2012-12-25 | Kyoto University | Agent for promoting the production of thioredoxin |
JP5043828B2 (ja) * | 2006-03-30 | 2012-10-10 | 国立大学法人京都大学 | チオレドキシン産生促進剤 |
JP2014209129A (ja) * | 2006-09-06 | 2014-11-06 | 日本臓器製薬株式会社 | 被検物質の評価方法 |
WO2008029836A1 (fr) * | 2006-09-06 | 2008-03-13 | Nippon Zoki Pharmaceutical Co., Ltd. | Procédé d'étude, de détermination ou d'évaluation |
US7923254B2 (en) | 2006-09-06 | 2011-04-12 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for studying, determining or evaluating pharmacological actions of a test substance on an sart stressed animal |
WO2008029838A1 (en) | 2006-09-06 | 2008-03-13 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for study, determination or evaluation by gene expression analysis |
JP2013156265A (ja) * | 2006-09-06 | 2013-08-15 | Nippon Zoki Pharmaceut Co Ltd | 研究、判定又は評価法 |
WO2008041751A1 (fr) | 2006-10-05 | 2008-04-10 | St. Marianna University School Of Medicine | Préparation pharmaceutique pour le traitement de la fibromyalgie |
JPWO2009025091A1 (ja) * | 2007-08-23 | 2010-11-18 | Mpo株式会社 | 線維筋痛症治療用医薬組成物 |
WO2009025091A1 (ja) * | 2007-08-23 | 2009-02-26 | St. Marianna University School Of Medicine | 線維筋痛症治療用医薬組成物 |
WO2009028605A1 (ja) | 2007-08-31 | 2009-03-05 | Kyushu University, National University Corporation | 抗がん剤による末梢神経障害の予防又は軽減剤 |
AU2008292407B2 (en) * | 2007-08-31 | 2013-12-12 | Kyushu University, National University Corporation | Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent |
US8613962B2 (en) | 2007-08-31 | 2013-12-24 | Kyushu University, National University Corporation | Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent |
JP5809620B2 (ja) * | 2010-03-11 | 2015-11-11 | 日本臓器製薬株式会社 | 慢性前立腺炎、間質性膀胱炎及び/又は排尿障害の改善又は治療剤 |
US9011849B2 (en) | 2010-03-11 | 2015-04-21 | Nippon Zoki Pharmaceutical Co., Ltd. | Ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders |
AU2011225222B2 (en) * | 2010-03-11 | 2015-08-27 | Nippon Zoki Pharmaceutical Co., Ltd. | Ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders |
WO2011111770A1 (ja) | 2010-03-11 | 2011-09-15 | 日本臓器製薬株式会社 | 慢性前立腺炎、間質性膀胱炎及び/又は排尿障害の改善又は治療剤 |
US9447466B2 (en) | 2010-06-25 | 2016-09-20 | Nippon Zoki Pharmaceutical Co., Ltd. | Method for determination or evaluation of test substance |
WO2011162317A1 (ja) | 2010-06-25 | 2011-12-29 | 日本臓器製薬株式会社 | 被検物質の判定又は評価方法 |
US10711292B2 (en) | 2010-10-14 | 2020-07-14 | Nikkon Zoki Pharmaceutical Co., Ltd. | Method for promoting the synthesis of collagen and proteoglycan in chondrocytes |
WO2014057995A1 (ja) * | 2012-10-10 | 2014-04-17 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
US11529374B2 (en) | 2012-10-10 | 2022-12-20 | Nippon Zoki Pharmaceutical Co., Ltd. | Extract and formulation including extract |
JP2014077779A (ja) * | 2013-04-19 | 2014-05-01 | Nippon Zoki Pharmaceut Co Ltd | 抽出物及び製剤 |
JPWO2014178394A1 (ja) * | 2013-04-30 | 2017-02-23 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
US9884077B2 (en) | 2013-04-30 | 2018-02-06 | Nippon Zoki Pharmaceutical Co., Ltd. | Extract and preparation containing said extract |
WO2014178394A1 (ja) * | 2013-04-30 | 2014-11-06 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
JP2014214154A (ja) * | 2013-08-23 | 2014-11-17 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
JP2014214155A (ja) * | 2013-11-19 | 2014-11-17 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
JP2016033145A (ja) * | 2015-11-20 | 2016-03-10 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
JPWO2017131169A1 (ja) * | 2016-01-29 | 2019-01-17 | 国立大学法人千葉大学 | 筋損傷の予防又は治療剤 |
US11207354B2 (en) | 2016-09-23 | 2021-12-28 | Osaka University | Schwann cell differentiation promoting agent and a peripheral nerve regeneration promoting agent |
JP2016216518A (ja) * | 2016-09-28 | 2016-12-22 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
Also Published As
Publication number | Publication date |
---|---|
KR20050072457A (ko) | 2005-07-11 |
CA2503810A1 (en) | 2004-05-13 |
CN1708311A (zh) | 2005-12-14 |
JP3887731B2 (ja) | 2007-02-28 |
US7148012B2 (en) | 2006-12-12 |
EP1566178A1 (en) | 2005-08-24 |
EP1566178B1 (en) | 2016-06-01 |
US20070218037A1 (en) | 2007-09-20 |
KR101097138B1 (ko) | 2011-12-22 |
US7435547B2 (en) | 2008-10-14 |
JPWO2004039383A1 (ja) | 2006-02-23 |
US7238487B2 (en) | 2007-07-03 |
CN100464782C (zh) | 2009-03-04 |
US20060263388A1 (en) | 2006-11-23 |
US20060051376A1 (en) | 2006-03-09 |
AU2003280684B2 (en) | 2009-06-25 |
AU2003280684A1 (en) | 2004-05-25 |
EP1566178A4 (en) | 2006-09-06 |
TW200412983A (en) | 2004-08-01 |
CA2503810C (en) | 2012-03-13 |
TWI342778B (en) | 2011-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3887731B2 (ja) | 線維筋痛症治療剤 | |
CN102058673B (zh) | 一种祛风除湿的中药组合物及其制备方法 | |
CA2792085C (en) | Ameliorating or therapeutic agent comprising an extract from inflamed tissue inoculated with vaccinia virus for chronic prostatitis, interstitial cystitis and/or urination disorders | |
WO2017146230A1 (ja) | 試験方法 | |
JP2004300146A (ja) | 感染防御剤 | |
CN106880654B (zh) | 竹节参提取物在制备治疗鼻炎药物中的应用及组合物 | |
JP7125732B2 (ja) | 神経因性膀胱の改善又は治療剤 | |
JP6966763B2 (ja) | 膝蓋軟骨軟化症の改善又は治療剤 | |
JP7125733B2 (ja) | 肢端紅痛症の改善又は治療剤 | |
CN114042109B (zh) | 一种通窍止涕、温阳固本的中药组合物、贴剂及制备方法 | |
CN109833380A (zh) | 用于预防和治疗湿疹的组合物 | |
JP6803678B2 (ja) | 帯状疱疹角膜炎の改善又は治療剤 | |
CN1098705C (zh) | 一种治疗脑神经系统疾病的口服药物及其制备方法 | |
CN105796933A (zh) | 一种治疗原发性三叉神经痛的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2006051376 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10532792 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2503810 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057007363 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A2599X Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003280684 Country of ref document: AU Ref document number: 2004548103 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003770087 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057007363 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003770087 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10532792 Country of ref document: US |